Uterine<unk>  was first discovered by Hippocrates in 460-375 B.C and called it  “uterine stone”. Uterine<unk>   may be classified according to their location into 3 subtypes: submucosal, subserous, and intramural. The pathogenesis of<unk>  is characterized by benign smooth muscle neoplasm. They can occur in any organ, but the most common forms occur in the uterus, small bowel and the esophagus. Chromosome aberrations such as t(12; 14)(q14-q15;q23–24), del(7)(q22q32), rearrangements involving 6p21, 10q, trisomy 12, and deletions of 1p3q has been associated with the development of<unk> . Uterine<unk>  must be differentiated from other diseases that cause uterine mass, such as: uterine adenomyoma, pregnancy, hematometra, uterine sarcoma, uterine carcinosarcoma, and metastasis.<unk>  is more commonly observed among patients aged 40 years and older. Common risk factors in the development of uterine<unk>  include African-American race, early menarche, prenatal exposure to diethylstilbestrol, having one or more pregnancies extending beyond 20 weeks, obesity, significant consumption of beef and other red meats, hypertension, family history, and alcohol consumption. Physical examination may be remarkable for enlarged, mobile uterus with an irregular contour on bimanual pelvic examination. The mainstay of therapy for uterine<unk>  is oral contraceptive pills, either combination pills or progestin-only, Gonadotropin-releasing hormone analogs. Surgery is also part of mainstay therapy for uterine<unk> .
Leiomyoma
Leiomyosarcoma
Uterine sarcoma
Endometriosis
Adenomyosis
Epithelial ovarian tumors
Intravenous leiomyomatosis
Uterine fibroids